Lung Cancer Clinical Trials

• Informed consent (radiation, medication) before treatment;

• Age 18 to 70 years old,regardless of gender;

• Initial SCLC confirmed by histopathological or cytological examination;

• Metastatic lesions in the distant area: included liver metastasis；

• Physical status score ECOG: 0 to 2；

• The expected survival time is more than 3 months;

• Bone marrow function:hemoglobin(HGB)\>90g/L,platelet(PLT)\>100×109/L,neutrophil cell(WBC)\>1.5×109/L(\*normal value);

• Liver function:alanine aminotransferase(ALT) and aspertate aminotransferase(AST)\<1.5 times of the upper limit of normal(ULN);Total bilirubin \<1.5ULN;

• Renal function:Serum creatinine was lower than 1.5ULN,and the endogenous creatinine clearance rate(Ccr) is higher than 55mL/min;

⁃ Initial treatment (previously did not receive any thoracic radiotherapy or surgery).